Deal Details

Emmes Receives Investment from New Mountain Capital

---

Summary

About

Emmes is a leading specialty CRO that provides its clients with the technologies and dedicated service required to manage clinical research studies with the highest standards of quality. The Company sits at the intersection of the public and private healthcare sectors with clients including biopharmaceutical companies, government agencies, foundations, academic institutions and other non-profit organizations. Emmes is proud to support the research efforts of agencies such as the National Institutes of Health (NIH), Food and Drug Administration (FDA), Department of Defense (DOD), Department of Health and Human Services (HHS) and Biomedical Advanced Research and Development Authority (BARDA). Emmes is headquartered in Rockville, Maryland.

Based in New York City, Behrman Capital was founded in 1991 by Grant G. and Darryl G. Behrman. Behrman Capital invests in management buyouts, leveraged buildups and recapitalizations of established growth businesses. Behrman Capital’s investments are focused in three industries: defense and aerospace, healthcare services, and specialty manufacturing and distribution. Behrman Capital has raised $4.0 billion since inception and is currently investing out of its sixth fund.

New Mountain Capital is a New York-based investment firm that emphasizes business building and growth, rather than debt, as it pursues long-term capital appreciation. New Mountain Capital currently manages private equity, credit, net lease real estate and public equity funds with over $37 billion in assets under management. New Mountain Capital seeks out what it believes to be the highest quality growth leaders in carefully selected industry sectors and then works intensively with management to build the value of these companies.

---

CONTACT US TO LEARN MORE